Noninvasive tests to assess hepatic fibrosis in fatty liver disease
| Test . | Fibrosis risk . | ||
|---|---|---|---|
| Low . | Intermediate . | High . | |
| LSM measured by TE (FibroScan) | <8 kPa | 8-13 kPa | >13 kPa |
| FIB4 Index∗ | <1.3 | 1.3-2.67 | >2.67 |
| AAR | <0.8 | 0.8-1 | >1 |
| NFS† | Less than –1.455 | –1.455 to 0.676 | >0.676 |
| MRE | <2.5 kPa | 2.5-4 kPa | >4 kPa |
| Test . | Fibrosis risk . | ||
|---|---|---|---|
| Low . | Intermediate . | High . | |
| LSM measured by TE (FibroScan) | <8 kPa | 8-13 kPa | >13 kPa |
| FIB4 Index∗ | <1.3 | 1.3-2.67 | >2.67 |
| AAR | <0.8 | 0.8-1 | >1 |
| NFS† | Less than –1.455 | –1.455 to 0.676 | >0.676 |
| MRE | <2.5 kPa | 2.5-4 kPa | >4 kPa |
Adapted from Di Minno et al56 with permission.
AAR, AST/ALT ratio; BMI, body mass index; FIB4, fibrosis 4; MRE, magnetic resonance elastography; NFS, nonalcoholic fatty liver disease fibrosis score.
Calculated as age × AST (IU/L)/platelet count (×109/L) × √ALT (IU/L).57
Calculated as 1.675 + 0.0373 × age (years) + 0.0943 BMI (kg/m2) + 1.133 × impaired fasting glycaemia or diabetes (yes = 1; no = 0) + 0.993 × AST/ALT ratio – 0.0133 × platelet (×109/L) – 0.663 × albumin (g/dL).58